Ubs Asset Management Americas Inc Sigilon Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$9.15 - $20.17 $1.13 Million - $2.49 Million
-123,374 Closed
0 $0
Q1 2021

May 14, 2021
SELL
$18.76 - $40.91 $30,503 - $66,519
-1,626 Reduced 1.3%
123,374 $2.76 Million
Q4 2020

Mar 01, 2021
BUY
$27.6 - $48.03 $3.45 Million - $6 Million
125,000 New
125,000 $6 Million

About Sigilon Therapeutics, Inc.

SGTX Quotes by TradingView
  • Ticker SGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,399,300
  • Description
  • Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...
More about SGTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email